The coagulation cascade in sepsis.

Wang L, Bastarache JA, Ware LB
Curr Pharm Des. 2008 14 (19): 1860-9

PMID: 18691097 · DOI:10.2174/138161208784980581

Intravascular and extravascular fibrin formation are characteristic findings in patients with sepsis, suggesting that the activation of coagulation and the inhibiton of fibrinolysis are important in the pathogenesis of sepsis. Activation of coagulation during sepsis is primarily driven by the tissue factor (TF) pathway, while inhibition of fibrinolysis is primarily due to increases in plasminogen activator inhibitor -1(PAI-1). Downregulation of the anticoagulant Protein C pathway also plays an important role in the modulation of coagulation and inflammation in sepsis. Recent advances in the understanding of pathogenetic mechanisms of coagulation and fibrinolysis in sepsis may have therapeutic implications. Recombinant human activated protein C (rhAPC) is currently the only pharmacologic therapy that has been shown to reduce mortality in adults with severe sepsis, highlighting the importance of coagulation and fibrinolysis as a therapeutic target in sepsis. This review summarizes recent basic and clinical findings with regard to the role of the coagulation cascade in sepsis and explores potential therapeutic targets in the coagulation and fibrinolytic pathways in the management of sepsis.

MeSH Terms (11)

Animals Blood Coagulation Drug Delivery Systems Fibrin Fibrinolysis Humans Plasminogen Activator Inhibitor 1 Protein C Recombinant Proteins Sepsis Thromboplastin

Connections (1)

This publication is referenced by other Labnodes entities: